Deutsche Bank Upgrades Morgan Stanley (MS) to Buy
Tweet
Share
E-mailGet Alerts MS Hot Sheet
Price: $217.36 -0.47%
Rating Summary:
22 Buy, 17 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
22 Buy, 17 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Deutsche Bank upgraded Morgan Stanley (NYSE: MS) from Hold to Buy with a price target of $30.00 (from $20.00). Analyst Matt O'Connor noted Morgan Stanley leverage to rising equity markets and interest rates.
"The stock trades at a modest discount to tangible book even though earnings momentum seems poised to accelerate. This expected ramp in EPS reflects the rise in equity markets YTD, the expected buy-in of the remaining JV stake, and less drag from FICC going forward, in our view. Over time, MS also has a lot of leverage to rising rates--which seems less reflected in MS shares vs. some other banks that are also well positioned for higher rates," said Matt O'Connor.
For an analyst ratings summary and ratings history on Morgan Stanley (NYSE: MS) click here. For more ratings news on Morgan Stanley click here.
Shares of Morgan Stanley closed at $24.98 yesterday.
"The stock trades at a modest discount to tangible book even though earnings momentum seems poised to accelerate. This expected ramp in EPS reflects the rise in equity markets YTD, the expected buy-in of the remaining JV stake, and less drag from FICC going forward, in our view. Over time, MS also has a lot of leverage to rising rates--which seems less reflected in MS shares vs. some other banks that are also well positioned for higher rates," said Matt O'Connor.
For an analyst ratings summary and ratings history on Morgan Stanley (NYSE: MS) click here. For more ratings news on Morgan Stanley click here.
Shares of Morgan Stanley closed at $24.98 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
- Movano (MOVE) Misses Q2 EPS by 195c
- Vivos Therapeutics posts 35% revenue gain but widens net loss
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS View, Hot Upgrades, UpgradesRelated Entities
Deutsche Bank, Morgan Stanley, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
